Results 91 to 100 of about 9,200 (223)

Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis [PDF]

, 2004
Alexandra Thompson, Janet Pope
openalex   +1 more source

Interleukin‐40 in Systemic Sclerosis: A Treatment‐Sensitive Marker of Immune Modulation Rather Than Disease Activity

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Interleukin‐40 (IL‐40) is a recently identified cytokine primarily produced by activated B cells and implicated in immune regulation across several autoimmune diseases. Although B cell–driven immune dysregulation plays a central role in systemic sclerosis (SSc), the circulating behavior and clinical relevance of IL‐40 in this disease remain ...
İbrahim Vasi, Emin Ümit Bağrıaçık, Rıza Can Kardaş, Nihan Örüklü, Melek Yaman, Derya Yıldırım, Burcugül Kaya, Rahime Duran, İbrahim Karaduman, İbrahim Yahya Çakır, Hamit Küçük, Berna Göker, Abdulsamet Erden, Mehmet Akif Öztürk   +13 more
wiley   +1 more source

Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis [PDF]

, 2004
Manuel Ramos‐Casals
openalex   +1 more source

Primary Biliary Cholangitis‐Associated Granulomatous Interstitial Lung Disease: Pulmonary Epithelial‐Interface Injury Supporting the Concept of Generalized Autoimmune Epithelitis

Pathology International, Volume 76, Issue 8, August 2026.
We report a rare case of primary biliary cholangitis‐associated granulomatous interstitial lung disease (PBC‐GILD) in a patient with coexisting anti‐synthetase syndrome. Bronchoalveolar lavage fluid revealed lymphocytosis with multinucleated giant cells.
Jiayao Liu, Yuki Kamikokura, Manami Hayashi, Akira Sakata, Naoko Aoki, Miki Saito, Yoshinori Minami, Takaaki Sasaki, Masahiro Kitada, Yukio Nakatani, Sayaka Yuzawa, Shin Ichihara, Mishie Tanino   +12 more
wiley   +1 more source

Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient‐Reported Assessments of Disease Severity [PDF]

, 2018
John D Pauling, Elizabeth Reilly, Theresa Smith, Tracy Frech   +3 more
openalex   +1 more source

Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database [PDF]

, 2020
Zaza Putkaradze, Matthieu Roustit, Cracowski Jean‐Luc, Charles Khouri   +3 more
openalex   +1 more source

PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology

Reumatismo
Background. To investigate whether age and timing of Raynaud’s phenomenon (RP) and non-Raynaud’s phenomenon (NRP) onset influence systemic sclerosis (SSc) endotype and prognosis.   Materials and Methods.
Società Italiana di Reumatologia
doaj  

Increased urinary pyridinoline cross‐link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon [PDF]

, 2001
R Istok, László Czirják, J Lukáč, M Stancíková, Jozef Rovenský   +4 more
openalex   +1 more source

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study [PDF]

, 1998
C. M. Black, L Halkier-Sørensen, J. J. F. Belch, Susanne Ullman, Rajan Madhok, Angelique Smit, Jan Dirk Banga, H R Watson   +7 more
openalex   +1 more source

FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD'S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY [PDF]

, 2019
Dinesh Khanna, Yannick Allanore, Christopher P. Denton, Masataka Kuwana, Marco Matucci‐Cerinic, Janet Pope, Janethe de Oliveria Pena, Kaisa Laapas, Zhen Yao, Melanie Hemmrich, Oliver Distler   +10 more
openalex   +1 more source